Why 4/5: It mandates a change in regulations for substance use disorder treatment, directly impacting providers and patient care.
This bill will require providers offering office-based buprenorphine treatment for opioid use disorder to offer counseling or referrals to counseling to patients. This change aims to enhance comprehensive care for addiction, while ensuring patients can still receive buprenorphine even if they decline counseling.
Cleared committee
Reported from Education and Health (13-Y 0-N)
Update
Rules suspended
Update
Constitutional reading dispensed (on 2nd reading) (40-Y 0-N 0-A)
Update
Passed by for the day (Voice Vote)
Third reading
Read third time
Passed a chamber
Passed Senate (38-Y 0-N 0-A)
Enrolled
Enrolled
Passed a chamber
Bill text as passed House and Senate (HB712ER)
Passed a chamber
Signed by Speaker
This bill has passed its votes and is headed to the Governor's desk. You still have a say — the Governor's office reads messages before deciding whether to sign.
New to all this? See how a bill becomes law →
Summarized from the official bill text (“Office-based buprenorphine treatment; Board of Medicine to amend regulations.”) · Read the actual bill →
Passed a chamber
Signed by President
Update
Fiscal Impact Statement from Department of Planning and Budget (HB712)
Enrolled
Enrolled Bill communicated to Governor on March 10, 2026
Sent to the Governor
Governor's Action Deadline 11:59 p.m., April 13, 2026
Signed into law
Approved by Governor-Chapter 207 (effective 7/1/2026)
Update
Acts of Assembly Chapter text (CHAP0207)